Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO1108 Herpes Zoster mRNA Vaccine in Adults Aged ≥40 Years
NCT07817108Phase 3Recruiting
- Sponsor
- Abogen Bioscience
- Start
- Jun 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in herpes zoster (HZ) comparing Group 1: Experimental (ABO1108) with Group 2: Placebo Control (2 arms). Primary endpoint: Confirmed herpes zoster incidence rate per person-year. Started Jun 2026; status: recruiting.
02
Drugs
ABO1108
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT07817108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07817108.